title: Quantification of kininogens in plasma. A functional method based on the cysteine proteinase inhibitor activity.
abstract: We have previously reported on a microassay based on human kininogens as cysteine proteinase inhibitors (CPIs), which could quantify partially purified kininogens from different biological fluids (J Pharmacol Meth 26, 113-124, 1991). In the present study we describe a functional method that, when assuming a 1:1 stoichiometry between papain and kininogen, allows a direct measurement of the molar concentration of kininogens in plasma. The principle of the method is that the target enzyme papain is inhibited by kininogens present in added diluted plasma. The residual activity of papain, not inhibited in this reaction, subsequently hydrolyzes the added peptide substrate (S-2302), generating a yellow colour which is read in a microplate reader at 405 nm. Relating the test samples to a standard curve established from known concentrations of E-64 (a selective low molecular weight inhibitor of cysteine proteinases), we could quantify kininogens on a molar basis. A major problem when first applying this method to plasma, was the interference of alpha 2-macroglobulin, which inhibited papain and generated a complex able to split the chromogenic substrate. The interference of alpha 2-macroglobulin was eliminated by an initial acid treatment of plasma followed by dilution with a buffer containing methylamine. The specificity for kininogens in this assay is demonstrated by the following observations: Commercial pooled normal plasma contained 3.2 microM CPI activity, in good agreement with the expected molar concentration of kininogens. After gel filtration of a plasma sample with a CPI activity of 3.4 microM, two peaks with CPI activity were identified as H-kininogen (0.9 microM) and L-kininogen (2.5 microM), both in good accordance with expected concentrations of the two kininogens. Plasma deficient of kininogens had a minimal inhibitory capacity towards papain.
authors.affiliation: Dept. of Pharmacology, School of Pharmacy, University of Oslo, Norway.
authors.forename: T S
authors.initials: TS
authors.lastname: Karlsrud
authors.forename: L
authors.initials: L
authors.lastname: Buø
authors.forename: A O
authors.initials: AO
authors.lastname: Aasen
authors.forename: H T
authors.initials: HT
authors.lastname: Johansen
mesh_terms: D000595:Amino Acid Sequence; D002021:Buffers; D015853:Cysteine Proteinase Inhibitors / Q000097:blood* / Q000737:chemistry; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007704:Kininogens / Q000097:blood* / Q000737:chemistry; D008969:Molecular Sequence Data; D010206:Papain / Q000037:antagonists & inhibitors / Q000097:blood; D010446:Peptide Fragments / Q000097:blood*
chemical_list: D002021:Buffers; D015853:Cysteine Proteinase Inhibitors; D007704:Kininogens; D010446:Peptide Fragments; D010206:Papain